| Literature DB >> 35431624 |
Gustavo DE Mello Ribeiro Pinto1, Jorge Henrique Assunção1, Maria Cristina Leme Godoy Dos Santos2, Alexandre Leme Godoy-Santos1, Mauro Emilio Conforto Gracitelli1, Eduardo Angeli Malavolta1, Fernando Brandão DE Andrade E Silva1, Arnaldo Amado Ferreira Neto1.
Abstract
Introduction: To evaluate the relationship between the genetic polymorphism of matrix metalloproteinases 1 and 13 and posttraumatic elbow stiffness, as well as the association of other risk factors with this condition. Materials and methods: We evaluated 20 patients with posttraumatic elbow stiffness and 12 controls with traumatic elbow disorders without contracture. Deoxyribonucleic acid (DNA) was obtained from buccal mucosa epithelial cells of the volunteers. The MMP-1 and MMP-13 genotypes were determined using PCR-restriction fragment length polymorphism assays.Entities:
Keywords: Articular rigidity; Capsule contracture; Elbow; Genetic polymorphism; Metalloproteinases; Trauma
Year: 2022 PMID: 35431624 PMCID: PMC8979351 DOI: 10.1590/1413-785220223001e253503
Source DB: PubMed Journal: Acta Ortop Bras ISSN: 1413-7852 Impact factor: 0.513
PCR-RFLP conditions for MMP-1 (rs1799750) and MMP-13 (rs2252070) polymorphisms.
| SNP | Primers (5'-3') | Anealling | RFLP | pb PCR-RFLP |
|---|---|---|---|---|
| MMP-1 | F: TCGTGAGAATGTCTTCCCATT | 55°C | XmnI | 118 (Allele 2G) |
| (rs1799750) | R: TCTTGGATTGATTTGAGATAAGTGAAATC | 30 s | 37°C | 89 + 29 (Allele 1G) |
| MMP-13 | F: GATACGTTCTTACAGAAGGC | 53°C | BsrI | 445 (Allele A) |
| (rs2252070) | R: ACAAATCATCTTCATCACC | 1 min | 65°C | 248 + 197 (Allele G) |
PCR-RFLP = polymerase chain reaction-restriction fragment length polymorphism; MMP = matrix metalloprotease; SNP = single nucleotide polymorphism; F = primer forward; R = primer reverse; bp = base pairs.
Baseline demographic and clinical characteristics.
| Cases | Controls | p | |
|---|---|---|---|
| Age (years) | 39.3±11 | 47.4±12.6 | 0.068 |
|
| |||
| Male | 14 (70%) | 6 (50%) | 0.258 |
| Female | 6 (30%) | 6 (50%) | |
|
| |||
| White | 10 (50%) | 6 (50%) | 0.999 |
| Nonwhite | 10 (50%) | 6 (50%) | |
|
| |||
| Yes | 10 (50%) | 7 (58%) | 0.647 |
| No | 10 (50%) | 5 (42%) | |
|
| |||
| Yes | 5 (25%) | 4 (33%) | 0.695 |
| No | 15 (75%) | 8 (67%) | |
|
| |||
| Low energy | 8 (40%) | 8 (67%) | 0.273 |
| High energy | 12 (60%) | 4 (33%) | |
|
| |||
| Surgical | 11 (55%) | 8 (67%) | 0.713 |
| Non-surgical | 9 (45%) | 4 (33%) | |
|
| |||
| Simple fracture | 9 (45%) | 8 (66%) | 0.398 |
| Comminuted fracture | 6 (30%) | 3 (25%) | |
| Dislocation | 5 (25%) | 1 (8%) | |
| Elbow immobilization time(days) | 15.7±10.7 | 6.9±7 | 0.015 |
| Time of physical therapy treatment (weeks) | 38.8±32.6 | 16±21 | 0.040 |
Distribution of the MMP-1 and MMP-13 allele in case and control groups.
| Cases | Controls | p | |
|---|---|---|---|
|
| |||
| 1G | 26 (65%) | 19 (79%) | 0.497 |
| 2G | 14 (35%) | 7 (21%) | |
|
| |||
| A | 30 (75%) | 15 (63%) | 0.289 |
| G | 10 (25%) | 9 (37%) |
Distribution of the MMP-1 and MMP-13 genotype in case and control groups.
| Cases | Controls | p | |
|---|---|---|---|
|
| |||
| 1G/1G | 7 (35%) | 6 (50%) | 0.599 |
| 1G/2G | 12 (60%) | 5 (42%) | |
| 2G/2G | 1 (5%) | 1 (8%) | |
|
| |||
| A/A | 11 (55%) | 4 (33%) | 0.491 |
| A/G | 8 (40%) | 7 (58%) | |
| G/G | 1 (5%) | 1 (8%) |